Literature DB >> 9669282

The smooth muscle cell: sinner or saint in restenosis and the acute coronary syndromes?

A Lafont, P Libby.   

Abstract

Proliferation of arterial smooth muscle cells has held center stage as the culprit in restenosis for almost two decades. Many strategies for combating restenosis target smooth muscle replication. However, none have proven beneficial in clinical trials. Indeed, inhibition of smooth muscle proliferation in human patients might produce the undesired effect of destabilizing vulnerable atherosclerotic plaques because these cells furnish the collagen responsible for the biomechanical strength of the plaque. Actually, in some cases the benefit of angioplasty may depend on stimulating smooth muscle replication and collagen elaboration, converting an "unstable" to a more stable plaque. Moreover, recent clinical and experimental evidence suggests that restenosis depends less on neointimal hyperplasia than on constrictive remodeling (i.e., advential scarring, producing a smaller lumen), a process independent of smooth muscle replication. The recognition that plaques vulnerable to disruption often do not produce flow-limiting stenoses highlights a need for reassessment of the strategies to treat or prevent the acute coronary syndromes. We should strive to treat aggressively risk factors such as hyperlipidemia whose control appears to stabilize plaques. Trials are even underway comparing such risk factor management with coronary artery intervention. If we could identify potentially unstable atheroma before they are evident, clinically, we might even contemplate angioplasty of nonsignificant stenoses to induce smooth muscle cell proliferation and reinforce the plaque's fibrous cap. This proposal may seem preposterous, yet we perform "primary" angioplasty every day in patients with an acute myocardial infarction whose "culprit" lesions underlying the thrombus are often not critical. Our knowledge of the biology of restenosis has lagged behind our practice of coronary intervention. Advances in understanding the biology of the complications of interventional therapy, hand in hand with technical advances, should help us to devise more rational and enduring approaches to benefiting our patients.

Entities:  

Mesh:

Year:  1998        PMID: 9669282     DOI: 10.1016/s0735-1097(98)00216-2

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  14 in total

1.  Raised interleukin 6 concentrations as a predictor of postangioplasty restenosis.

Authors:  T Suzuki; S Ishiwata; K Hasegawa; K Yamamoto; T Yamazaki
Journal:  Heart       Date:  2000-05       Impact factor: 5.994

2.  Plasma fibrinogen, soluble P-selectin, and von Willebrand factor in aortic valve disease: evidence for abnormal haemorheology, platelet activation, and endothelial dysfunction.

Authors:  I R Goldsmith; A D Blann; R L Patel; G Y Lip
Journal:  Heart       Date:  2000-05       Impact factor: 5.994

Review 3.  Antiinflammatory and immunomodulatory properties of statins.

Authors:  Ora Shovman; Yair Levy; Boris Gilburd; Yehuda Shoenfeld
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

4.  Influence of sustained mechanical stress on Egr-1 mRNA expression in cultured human endothelial cells.

Authors:  M Stula; H D Orzechowski; S Gschwend; R Vetter; R von Harsdorf; R Dietz; M Paul
Journal:  Mol Cell Biochem       Date:  2000-07       Impact factor: 3.396

Review 5.  Plaque sealing by coronary angioplasty.

Authors:  B Meier
Journal:  Heart       Date:  2004-12       Impact factor: 5.994

Review 6.  Basic aspects of plaque vulnerability.

Authors:  Antoine Lafont
Journal:  Heart       Date:  2003-10       Impact factor: 5.994

7.  Hyperlipemia and oxidation of LDL induce vascular smooth muscle cell growth: an effect mediated by the HLH factor Id3.

Authors:  Angela M Taylor; Feng Li; Pushpa Thimmalapura; Ross G Gerrity; Ian J Sarembock; Scott Forrest; Sarah Rutherford; Coleen A McNamara
Journal:  J Vasc Res       Date:  2005-12-07       Impact factor: 1.934

Review 8.  Pathophysiology of atherosclerosis: development, regression, restenosis.

Authors:  M R Adams; S Kinlay; G J Blake; J L Orford; P Ganz; A P Selwyn
Journal:  Curr Atheroscler Rep       Date:  2000-05       Impact factor: 5.113

9.  Tissue factor pathway inhibitor-2 is a novel inhibitor of matrix metalloproteinases with implications for atherosclerosis.

Authors:  M P Herman; G K Sukhova; W Kisiel; D Foster; M R Kehry; P Libby; U Schönbeck
Journal:  J Clin Invest       Date:  2001-05       Impact factor: 14.808

10.  Distance from the coronary ostium to the culprit lesion in acute ST-elevation myocardial infarction and its implications regarding the potential prevention of proximal plaque rupture.

Authors:  C Michael Gibson; Ajay J Kirtane; Sabina A Murphy; Juhana Karha; Christopher P Cannon; Robert P Giugliano; Mathew T Roe; Robert A Harrington; E Magnus Ohman; Elliott M Antman
Journal:  J Thromb Thrombolysis       Date:  2003-06       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.